Table 2.
Annual Incidence (Cases per 100 000 Persons) of Pneumococcal Meningitisa,b by Serotype Groups and Patient Age, Burkina Faso, 2011–2017
| Serotype group and patient age category | Pre-PCV13 2011–2013 |
2014 | 2015 | 2016 | 2017 | Percentage Change (95% Confidence Interval) |
|
|---|---|---|---|---|---|---|---|
| 2016 Only vs 2011–2013 | 2017 Only vs 2011–2013 | ||||||
| All pneumococcal meningitis cases | 5.6 | 4.1 | 3.9 | 3.4 | 2.7 | −39% (−45% to −33%) | −52% (−57% to −46%) |
| <1 year | 26.9 | 13.7 | 8.7 | 9.0 | 10.5 | −66% (−74% to −56%) | −61% (−70% to −49%) |
| 1–4 years | 5.4 | 3.2 | 2.4 | 3.3 | 3.8 | −39% (−53% to −20%) | −30% (−46% to −10%) |
| 5–14 years | 7.2 | 6.2 | 6.5 | 5.2 | 3.5 | −27% (−38% to −15%) | −52% (−59% to −43%) |
| ≥15 years | 3.0 | 2.5 | 2.6 | 1.9 | 1.4 | −36% (−47% to −23%) | −54% (−63% to −44%) |
| PCV13 serotypes | 4.0 | 3.1 | 2.7 | 2.0 | 1.5 | −49% (−55% to −42%) | −62% (−67% to −57%) |
| <1 year | 17.3 | 7.9 | 4.2 | 3.8 | 4.0 | −78% (−86% to −67%) | −77% (−84% to −65%) |
| 1–4 years | 3.6 | 2.4 | 1.5 | 1.3 | 2.0 | −63% (−75% to −46%) | −44% (−60% to −22%) |
| 5–14 years | 5.3 | 4.8 | 4.5 | 3.6 | 2.1 | −33% (−44% to −19%) | −61% (−69% to −52%) |
| ≥15 years | 2.1 | 1.9 | 1.7 | 1.3 | 0.8 | −37% (−49% to −21%) | −64% (−72% to −53%) |
| Non-PCV13 serotypes | 0.7 | 0.6 | 0.4 | 0.5 | 0.3 | −27% (−44% to −5%) | −53% (−65% to −37%) |
| <1 year | 5.0 | 4.2 | 1.6 | 2.8 | 1.6 | −44% (−68% to −4%) | −68% (−84% to −39%) |
| 1–4 years | 0.6 | 0.3 | 0.1 | 0.7 | 0.4 | 21% (−38% to 135%) | −29% (−67% to 50%) |
| 5–14 years | 0.9 | 0.7 | 0.8 | 0.6 | 0.4 | −39% (−61% to −4%) | −57% (−74% to −30%) |
| ≥15 years | 0.4 | 0.2 | 0.4 | 0.3 | 0.2 | −35% (−60% to 5%) | −52% (−72% to −19%) |
| Nontypeable specimens | 0.9 | 0.4 | 0.8 | 0.8 | 0.8 | −6% (−25% to 18%) | −3% (−23% to 20%) |
| <1 year | 4.6 | 1.6 | 2.9 | 2.5 | 4.9 | −45% (−69% to −3%) | 7% (−33% to 71%) |
| 1–4 years | 1.2 | 0.5 | 0.9 | 1.3 | 1.3 | 8% (−34% to 77%) | 11% (−32% to 81%) |
| 5–14 years | 0.9 | 0.7 | 1.1 | 1.1 | 1.0 | 18% (−20% to 72%) | 8% (−26% to 59%) |
| ≥15 years | 0.5 | 0.4 | 0.4 | 0.3 | 0.4 | −31% (−56% to 8%) | −13% (−43% to 33%) |
| PCV13 serotypes excluding serotype 1 | 1.5 | 1.0 | 0.5 | 0.3 | 0.3 | −78% (−83% to −71%) | −79% (−84% to −72%) |
| <1 year | 14.0 | 6.6 | 2.9 | 1.8 | 1.8 | −87% (−93% to −78%) | −87% (−93% to −78%) |
| 1–4 years | 2.4 | 1.5 | 0.6 | 0.3 | 0.6 | −88% (−94% to −74%) | −73% (−84% to −54%) |
| 5–14 years | 1.1 | 0.9 | 0.6 | 0.5 | 0.3 | −56% (−72% to −29%) | −76% (−86% to −56%) |
| ≥15 years | 0.4 | 0.4 | 0.3 | 0.2 | 0.1 | −58% (−76% to −26%) | −75% (−87% to −50%) |
| Serotype 1 | 2.5 | 2.2 | 2.2 | 1.7 | 1.2 | −31% (−41% to −21%) | −52% (−59% to −44%) |
| <1 year | 3.3 | 1.3 | 1.3 | 2.0 | 2.2 | −39% (−68% to 17%) | −32% (−74% to 27%) |
| 1–4 years | 1.2 | 0.9 | 0.9 | 1.0 | 1.4 | −17% (−50% to 39%) | 13% (−30% to 80%) |
| 5–14 years | 4.2 | 4.0 | 3.9 | 3.1 | 1.8 | −27% (−40% to −11%) | −58% (−67% to −47%) |
| ≥15 years | 1.7 | 1.5 | 1.4 | 1.2 | 0.7 | −32% (−47% to −14%) | −62% (−71% to −49%) |
Abbreviations: CSF, cerebrospinal fluid; PCV13, 13-valent pneumococcal conjugate vaccine.
a
Streptococcus pneumoniae isolated from CSF by culture or detected in CSF by real-time polymerase chain reaction or latex agglutination.
b
Incidence adjusted for the proportion of cases with CSF tested at a national laboratory.